ALTIMMUNE, INC. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3
ALTIMMUNE, INC. (ALT) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Notes › Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3 · last filed 2026-03-06
- ALTIMMUNE, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2022-03-31 was $0.00.
- ALTIMMUNE, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2021-12-31 was $0.00.
- ALTIMMUNE, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2025 was $0.00.
- ALTIMMUNE, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2024 was $0.00.
- ALTIMMUNE, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2023 was $0.00.
- ALTIMMUNE, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2022 was $0.00.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-06 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-06 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-27 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |